Megaport Shares Plunge 20%: Analyst Views Split on Whether Selloff Is Overdone

The Quick Take

• Megaport (ASX: MP1) shares fell roughly 20% in a sharp single-session selloff that ranks among the stock's steepest drawdowns in recent years
• The network-as-a-service company has faced investor scrutiny over its path to sustained profitability as revenue growth slows from hypergrowth rates
• Analysts are divided on whether the decline represents a buying opportunity for long-term holders or a rational re-rating of elevated growth expectations

Megaport shares dropped roughly 20% in what analysts are describing as one of the stock's most significant single-day declines. The ASX-listed network-as-a-service provider, which connects enterprises to cloud platforms including AWS, Azure and Google Cloud via its Software Defined Network, has faced persistent questions about the pace of its revenue growth relative to its operating cost structure. The selloff appears to reflect a combination of earnings or guidance disappointment and broader risk-off sentiment towards high-multiple growth technology names on the ASX.

Megaport operates in a structurally growing market as enterprises accelerate their migration to multi-cloud environments and demand flexible, software-defined connectivity. However, the company has struggled to convert strong top-line momentum into consistent EBITDA margins at the pace that institutional investors had modelled. Customer count growth and port additions remain positive indicators, but the unit economics per port and average revenue per customer have drawn scrutiny as the company expands into more price-competitive geographic markets.

For investors evaluating the post-selloff entry point, the key variables are Megaport's updated revenue guidance trajectory, its progress on positive free cash flow generation, and whether the latest results indicate structural pricing pressure or a more temporary volume softness. The stock has historically been volatile around reporting seasons, and significant drawdowns have in past cycles represented buying opportunities for patient holders willing to accept near-term earnings uncertainty. The decisive variable will be whether management can provide a credible re-acceleration narrative.

Synthesized from 1 source.